Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue
3rd March 2026 Uncategorised 0The European Medicines Agency’s Committee for Medicinal Products for Human Use turned down Acadia’s Daybue application for Rett syndrome in late February based on concerns with the company’s pivotal trial.
More: Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue
Source: fierce